127 related articles for article (PubMed ID: 33280474)
1. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
2. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Zucenka A; Griskevicius L
Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
[TBL] [Abstract][Full Text] [Related]
4. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Qiao X; Ma J; Knight T; Su Y; Edwards H; Polin L; Li J; Kushner J; Dzinic SH; White K; Wang J; Lin H; Wang Y; Wang L; Wang G; Taub JW; Ge Y
Blood Cancer J; 2021 Jun; 11(6):111. PubMed ID: 34099621
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
Janssen M; Schmidt C; Bruch PM; Blank MF; Rohde C; Waclawiczek A; Heid D; Renders S; Göllner S; Vierbaum L; Besenbeck B; Herbst SA; Knoll M; Kolb C; Przybylla A; Weidenauer K; Ludwig AK; Fabre M; Gu M; Schlenk RF; Stölzel F; Bornhäuser M; Röllig C; Platzbecker U; Baldus C; Serve H; Sauer T; Raffel S; Pabst C; Vassiliou G; Vick B; Jeremias I; Trumpp A; Krijgsveld J; Müller-Tidow C; Dietrich S
Blood; 2022 Dec; 140(24):2594-2610. PubMed ID: 35857899
[TBL] [Abstract][Full Text] [Related]
6. Sweet syndrome induced by FLT3 inhibitors: case report and literature review.
Yang L; Zhang R; Ma H
Hematology; 2024 Dec; 29(1):2337230. PubMed ID: 38563968
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hypereosinophilia in a case of
Martinez-Gutierrez LN; Burgher BC; Glynias MJ; Alvarado D; Griffiths EA; Glenn ST; Sung PJ
Cold Spring Harb Mol Case Stud; 2023 Jun; 9(3):. PubMed ID: 37433680
[TBL] [Abstract][Full Text] [Related]
9. [Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib].
Koyama G; Kawaguchi T; Sato T; Hamada C; Hara S
Rinsho Ketsueki; 2024; 65(4):231-236. PubMed ID: 38684432
[TBL] [Abstract][Full Text] [Related]
10. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract][Full Text] [Related]
11. A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.
Appukkuttan S; Duchesneau E; Zichlin ML; Bhak RH; Yaldo A; Gharibo M; Babajanyan S; Duh MS
J Manag Care Spec Pharm; 2019 Apr; 25(4):437-446. PubMed ID: 30608008
[TBL] [Abstract][Full Text] [Related]
12. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Lin SW; Shapouri S; Parisé H; Bercaw E; Wu M; Kim E; Matasar M
Pharmacoeconomics; 2024 May; 42(5):569-582. PubMed ID: 38300452
[TBL] [Abstract][Full Text] [Related]
14. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.
Joshi SK; Nechiporuk T; Bottomly D; Piehowski PD; Reisz JA; Pittsenbarger J; Kaempf A; Gosline SJC; Wang YT; Hansen JR; Gritsenko MA; Hutchinson C; Weitz KK; Moon J; Cendali F; Fillmore TL; Tsai CF; Schepmoes AA; Shi T; Arshad OA; McDermott JE; Babur O; Watanabe-Smith K; Demir E; D'Alessandro A; Liu T; Tognon CE; Tyner JW; McWeeney SK; Rodland KD; Druker BJ; Traer E
Cancer Cell; 2021 Jul; 39(7):999-1014.e8. PubMed ID: 34171263
[TBL] [Abstract][Full Text] [Related]
15. Post-stem cell transplant maintenance in FLT3
Ashouri K; Chennapan K; Martynova A; Nazaretyan S; Ali A; Ginosyan AA; Tam E; Ladha A; Woan K; Chaudhary P; Siddiqi I; Yaghmour G
EJHaem; 2024 Apr; 5(2):423-427. PubMed ID: 38633126
[No Abstract] [Full Text] [Related]
16. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
Leuk Res; 2024 Apr; 141():107505. PubMed ID: 38692232
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
Zhao X; Wang P; Diedrich JD; Smart B; Reyes N; Yoshimura S; Zhang J; Yang W; Barnett K; Xu B; Li Z; Huang X; Yu J; Crews K; Yeoh AEJ; Konopleva M; Wei CL; Pui CH; Savic D; Yang JJ
Nat Commun; 2022 Sep; 13(1):5401. PubMed ID: 36104354
[TBL] [Abstract][Full Text] [Related]
18. Potentiating Gilteritinib Efficacy Using Nanocomplexation with a Hyaluronic Acid-Epigallocatechin Gallate Conjugate.
Bae KH; Lai F; Chen Q; Kurisawa M
Polymers (Basel); 2024 Jan; 16(2):. PubMed ID: 38257023
[TBL] [Abstract][Full Text] [Related]
19. Budget impact of the Walk With Ease program for knee osteoarthritis.
Kumara MT; Cleveland RJ; Kostic AM; Weisner SE; Allen KD; Golightly YM; Welch H; Dale M; Messier SP; Hunter DJ; Katz JN; Callahan LF; Losina E
Osteoarthr Cartil Open; 2024 Jun; 6(2):100463. PubMed ID: 38562164
[TBL] [Abstract][Full Text] [Related]
20. FLT3 agonists and secondary hematopoietic malignancies: a potential class effect.
Raeder HW; Drazer MW
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38652676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
